A5082806411- Histiocytic Disorders and Treatments
- Melanoma and MAPK Pathways
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Mast cells and histamine
- Synthesis and biological activity
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Cancer Mechanisms and Therapy
- Extracellular vesicles in disease
- Tumors and Oncological Cases
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Parvovirus B19 Infection Studies
- Brain Metastases and Treatment
- interferon and immune responses
- Neuroblastoma Research and Treatments
- Viral-associated cancers and disorders
- Chromatin Remodeling and Cancer
- Genetic factors in colorectal cancer
- Childhood Cancer Survivors' Quality of Life
- Lung Cancer Treatments and Mutations
- Sarcoidosis and Beryllium Toxicity Research
- Genetic and rare skin diseases.
- Functional Brain Connectivity Studies
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2015-2024
Kettering University
2014-2024
Lenox Hill Hospital
2024
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2024
Histiocyte Society
2024
Cincinnati Children's Hospital Medical Center
2022
Hoag Memorial Hospital Presbyterian
2021
University of Miami
2020
Sylvester Comprehensive Cancer Center
2020
BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib mutation-positive cancers.We enrolled patients six prespecified cancer cohorts; with all other tumor types were seventh cohort. A total 122 treated, including 27 colorectal who received and cetuximab. The primary end point was the response rate; secondary points included progression-free overall survival.In cohort non-small-cell lung cancer, rate 42% (95%...
Omega3 fatty acids may inhibit neuronal signal transduction pathways in a manner similar to that of lithium carbonate and valproate, 2 effective treatments for bipolar disorder. The present study was performed examine whether omega3 also exhibit mood-stabilizing properties disorder.A 4-month, double-blind, placebo-controlled study, comparing (9.6 g/d) vs placebo (olive oil), addition usual treatment, 30 patients with Kaplan-Meier survival analysis the cohort found acid patient group had...
Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans (non-LCH), respectively. The discovery BRAF(V600E) mutations approximately 50% these patients provided the first molecular therapeutic target histiocytosis. However, recurrent driving majority with BRAF(V600E)-wild-type non-LCH unknown, cooperating non-MAP kinase pathways undefined for...
The neural underpinnings of age-related memory impairment remain to be fully elucidated. Using a subsequent face–name functional MRI (fMRI) paradigm, young and old adults showed similar magnitude extent hippocampal activation during successful associative encoding. Young demonstrated greater deactivation (task-induced decrease in BOLD signal) medial parietal regions compared with failed encoding, whereas as group did not demonstrate differential pattern between trial types. failure was...
<h3>Importance</h3> The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for<i>BRAF</i>V600 mutations have been previously shown to be responsive treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, long-term efficacy safety prolonged vemurafenib use in these patients not defined. Here we analyze final data for ECD LCH enrolled VE-BASKET study. <h3>Objective</h3> To determine adults or <h3>Design, Setting,...
Abstract Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management LCH are mostly derived from pediatric literature. Over last decade, discovery clonality MAPK-ERK pathway mutations most cases led to recognition as hematopoietic neoplasm, opening doors for treatment targeted therapies. These...
<h3>Objective</h3> To investigate the relationship between magnetic resonance imaging regional lesion burden and cognitive performance in multiple sclerosis (MS) over a 4-year follow-up period. <h3>Design</h3> Twenty-eight patients with MS underwent took Brief, Repeatable Battery of Neuropsychological Tests Multiple Sclerosis at baseline, 1-year, follow-up. An automated 3-dimensional detection method was used to identify lesions within anatomical regions on proton density T2-weighted images....
Abstract Purpose: The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile progression treatment response remain poorly understood. Experimental Design: We integrated prospective clinical sequencing 1,004 primary recurrent tumors from 923 glioma patients with phenotypes. Results: Thirteen percent harbored a pathogenic germline variant, including subset associated heritable genetic syndromes variants...
Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF(V600E) mutations respond to RAF inhibitors. However, detection in tissue biopsies is particularly challenging histiocytoses due low tumor content stromal contamination. We applied droplet-digital PCR assay for quantitative the mutation plasma urine cell-free (cf) DNA performed prospective, blinded study 30 patients ECD/LCH. There was 100% concordance between urinary cfDNA...
Abstract BRAF V600 mutations occur in a wide range of tumor types, and RAF inhibition has become standard several these cancers. Despite this progress, BRAFV600 have historically been considered clear demonstration lineage context–dependent oncogene addiction, based predominantly on the insensitivity to colorectal cancer. However, true broader activity pan-cancer remains incompletely understood. To address this, we conducted multicohort “basket” study inhibitor vemurafenib non-melanoma...
Abstract ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented case reports series to occupy wider clinicopathologic spectrum recurrent KIF5B-ALK fusions. The full molecular spectra remain, however, poorly characterized. Here, we describe largest study date, detailed data 39 cases, including 37 cases confirmed ALK...
Abstract Caregivers of patients with glioblastoma multiforme (GBM) are at significant risk for existential distress. Such distress negatively impacts caregivers’ quality life and capacity to serve in their role as healthcare proxies, ultimately, contributes poor bereavement outcomes. Our team developed Meaning-Centered Psychotherapy Cancer (MCP-C), the first targeted psychosocial intervention that directly addresses caregivers. The purpose this study was evaluate feasibility, acceptability,...
Abstract Erdheim-Chester disease (ECD) and Rosai-Dorfman (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark correlates with favorable response to BRAF inhibitors the MEK inhibitor cobimetinib. However, there has been no systematic evaluation of alternative inhibitors. To assess efficacy safety trametinib, we retrospectively analyzed...